New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 6, 2014
06:49 EDTSCMPSucampo to present data for lubiprostone
Sucampo Pharmaceuticals announced that clinical data for lubiprostone will be presented at the American Pain Society Conference in Tampa, Florida and Digestive Disease Week, or DDW, 2014 in Chicago, Illinois. Posters include: efficacy of lubiprostone for the treatment of opioid-induced constipation according to opioid class Poster 452; Lubiprostone for Treatment of Opioid-Induced Constipation: Analysis of Response by Opioid Class; a Pooled Analysis of Response to Lubiprostone in Patients With Opioid-Induced Constipation Receiving Non-Methadone Opioids Versus Methadone; nausea Reported by Patients Enrolled in Clinical Studies of Lubiprostone: Analysis of Well-Controlled and Long-Term, Open-Label Studies of Chronic Idiopathic Constipation, Opioid-Induced Constipation, and Irritable Bowel Syndrome With Constipation; the CIC-2 chloride channel activator, lubiprostone, prevents ileal epithelial permeability alterations in a murine model of diarrhea-predominant irritable bowel syndrome.
News For SCMP From The Last 14 Days
Check below for free stories on SCMP the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 22, 2014
15:12 EDTSCMPSucampo says FDA approves addition of Nitto Medic as Rescula production site
Sucampo Pharmaceuticals disclosed in a regulatory filing that on July 15 the company received an approval letter from the FDA to its prior approval supplement in response to FDAs review of the revised Drug Master File of R-Tech Ueno. The approval provides for the addition of Nitto Medic of Toyama, Japan as a new production site for Rescula 0.15%. "The company has adequate supply of RESCULA to be able to supply the U.S. market into the first quarter of 2015," Sucampo added.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use